中西医结合治疗乙肝后肝硬化对血清中ALT、AST、AST/ALT水平的影响
|
摘要
目的分析中西医结合治疗乙型肝炎(乙肝)后肝硬化对患者血清中谷丙转氨酶(ALT)、谷草转氨酶(AST)、AST/ALT水平的影响。方法 100例乙肝后肝硬化患者,随机分为研究组及对照组,各50例。研究组采用中西医结合治疗,对照组采用西医治疗。比较两组患者治疗3、6、12个月后血清中ALT、AST、AST/ALT水平情况。结果治疗3个月后,研究组患者的ALT、AST水平分别为(115.21±21.65)、(124.33±28.17) U/L,均低于对照组的(170.55±21.23)、(197.26±30.77) U/L,差异均具有统计学意义(P<0.05)。治疗6个月后,研究组患者的ALT、AST水平分别为(60.17±17.21)、(82.59±11.77) U/L,均低于对照组的(103.56±16.06)、(116.76±13.36) U/L,差异均具有统计学意义(P<0.05)。治疗12个月后,研究组患者的ALT、AST水平分别为(23.17±6.19)、(32.14±3.57) U/L,均低于对照组的(60.11±5.56)、(62.71±4.77) U/L,差异均具有统计学意义(P<0.05)。治疗3、6、12个月后,两组患者的AST/ALT水平比较,差异均无统计学意义(P>0.05)。结论对乙肝后肝硬化患者予以中药方剂联合恩替卡韦治疗,有助于改善患者血清中的ALT、 AST水平,能够取得更为理想的临床治疗效果。
Objective To analyze the effect of integrated traditional Chinese and Western medicine on serum levels of alanine aminotransferase(ALT), aspartate aminotransferase(AST) and AST/ALT in patients with post-hepatitis B cirrhosis. Methods A total of 100 patients with post-hepatitis B cirrhosis were randomly divided into research group and control group, with 50 cases in each group. The research group received integrated traditional Chinese and Western medicine for treatment, and the control group received Western medicine for treatment. Comparison were made on serum ALT, AST and AST/ALT levels after 3, 6 and 12 months of treatment between the two groups. Results After 3 months of treatment, the research group had ALT and AST level respectively as(115.21±21.65) and(124.33±28.17) U/L, which were all lower than(170.55±21.23) and(197.26±30.77) U/L in the control group, and their difference was statistically significant(P<0.05). After 6 months of treatment, the research group had lower ALT and AST level respectively as(60.17±17.21) and(82.59±11.77) U/L than(103.56±16.06) and(116.76±13.36) U/L in the control group, and their difference was statistically significant(P<0.05). After 12 months of treatment, the research group had lower ALT and AST level respectively as(23.17±6.19) and(32.14±3.57) U/L than(60.11±5.56) and(62.71±4.77) U/L in the control group, and their difference was statistically significant(P<0.05). After 3, 6 and 12 months of treatment, both groups had no statistically significant difference in AST/ALT level(P>0.05). Conclusion Combination of Chinese medicical formulae and entecavir helps improve the serum ALT and AST of patients with post-hepatitis B cirrhosis, and can achieve more ideal clinical treatment effect.
Objective To analyze the effect of integrated traditional Chinese and Western medicine on serum levels of alanine aminotransferase(ALT), aspartate aminotransferase(AST) and AST/ALT in patients with post-hepatitis B cirrhosis. Methods A total of 100 patients with post-hepatitis B cirrhosis were randomly divided into research group and control group, with 50 cases in each group. The research group received integrated traditional Chinese and Western medicine for treatment, and the control group received Western medicine for treatment. Comparison were made on serum ALT, AST and AST/ALT levels after 3, 6 and 12 months of treatment between the two groups. Results After 3 months of treatment, the research group had ALT and AST level respectively as(115.21±21.65) and(124.33±28.17) U/L, which were all lower than(170.55±21.23) and(197.26±30.77) U/L in the control group, and their difference was statistically significant(P<0.05). After 6 months of treatment, the research group had lower ALT and AST level respectively as(60.17±17.21) and(82.59±11.77) U/L than(103.56±16.06) and(116.76±13.36) U/L in the control group, and their difference was statistically significant(P<0.05). After 12 months of treatment, the research group had lower ALT and AST level respectively as(23.17±6.19) and(32.14±3.57) U/L than(60.11±5.56) and(62.71±4.77) U/L in the control group, and their difference was statistically significant(P<0.05). After 3, 6 and 12 months of treatment, both groups had no statistically significant difference in AST/ALT level(P>0.05). Conclusion Combination of Chinese medicical formulae and entecavir helps improve the serum ALT and AST of patients with post-hepatitis B cirrhosis, and can achieve more ideal clinical treatment effect.
引文
[1]张秀红.研究中西医疗法在乙肝肝硬化治疗中的安全性Meta分析.临床研究, 2016, 24(2):22-23.
[2]程无为.中西医结合治疗乙肝后肝硬化腹水34例.光明中医,2016, 31(18):2710-2711.
[3]郭志勇.中西医结合治疗乙肝肝硬化顽固性腹水的临床效果观察.现代诊断与治疗, 2015, 26(7):1470-1471.
[4]张华平.中西医结合治疗乙肝肝硬化顽固性腹水疗效分析.实用中医药杂志, 2017, 33(5):538-539.
[5]岑成灿.中西医结合治疗早期乙肝肝硬化的疗效观察.广西中医药, 2016, 39(3):34-35.
[6]梁予峰.中西医结合治疗乙肝肝硬化临床疗效和安全性的Meta分析.中国继续医学教育, 2015, 7(17):196-197.
[2]程无为.中西医结合治疗乙肝后肝硬化腹水34例.光明中医,2016, 31(18):2710-2711.
[3]郭志勇.中西医结合治疗乙肝肝硬化顽固性腹水的临床效果观察.现代诊断与治疗, 2015, 26(7):1470-1471.
[4]张华平.中西医结合治疗乙肝肝硬化顽固性腹水疗效分析.实用中医药杂志, 2017, 33(5):538-539.
[5]岑成灿.中西医结合治疗早期乙肝肝硬化的疗效观察.广西中医药, 2016, 39(3):34-35.
[6]梁予峰.中西医结合治疗乙肝肝硬化临床疗效和安全性的Meta分析.中国继续医学教育, 2015, 7(17):196-197.